Pharmacogenomics Reporter | December 12, 2007

Search the GenomeWeb Intelligence Network

Advanced Search

Pharmacogenomics Reporter
GenomeWeb News Premium Content
Existing subscribers login here.
New to Pharmacogenomics Reporter? For a trial subscription click here.

Volume 5 - Number 48 | December 12, 2007

Subscriber Login
Subscribe to Pharmacogenomics Reporter
Site Licenses
RSS Feed
Archives

In This Week's Issue

Columbia Researchers’ New SBS Method Combines Sanger with Reversible Termination

ABI’s Patent Suit Against Illumina, Former IP Counsel Set to Go to Trial This Fall

Oxford’s Hagan Bayley on Sequencing DNA With Engineered Protein Nanopores

Helicos BioSciences, General Electric Capital Corporation, Applied Biosystems, Celera, Invitrogen, Genome Quebec, Montreal Heart Institute, Blood Center Linz, Roche, Mars, USDA, IBM, Wellcome Trust Case Control Consortium 2, Sequenom, California Department of Public Health, Knome, NIH, Field Museum of Natural History, University of Florida, University of Cambridge

FinchLab Next Gen Edition

Sam Levy, Karen Nelson, Yu-Hui Rogers, Robert Friedman, Richard Lussier, James Pardee, William Green, Gail Naughton

Features

J&J Official Discusses How PGx Helps Company Set �Realistic Expectations�
The drug maker uses PGx strategies in three principal ways: to strengthen its pharmacokinetics R&D programs, to improve drug safety and efficacy, and to select trial patients most likely to respond to its products.

Dx Shops� Flexibility Will Encourage Co-Development Alliances, Qiagen CEO
In today’s risk-averse regulatory and reimbursement environment, “the pharmaceutical industry cannot take more risk into their projects at very early phases,” Qiagen CEO Peer Schatz said at a personalized medicine conference last month hosted by HPCGG.

HHS Chief Leavitt May Leave in �09; Vows To Keep Personalized Medicine Center Stage
Leavitt does not expect to stay on as HHS secretary when a new administration enters the White House in January 2009. However, he and his staff are trying to ensure that the personalized healthcare initiatives they launched remain after their tenure runs out.

Snippets

Rules-Based Medicine, EMD Chemicals, Luminex, Gene Logic, Nanogen, CDC, Clinical Data, Merck KgaA, TrimGen, FDA, Beckman Coulter, Thomas Jefferson University, Laboraf Diagnostica e Ricerca San Raffaele, Third Wave Technologies, NCI

Pairings

Ronen Tamir, Seymour Benzer, Sal Sanci, Paul Ford, James DeGeef, Don Listwin